Herpes Zoster Aspectos clínicos y terapéuticos
Abstract
Se prensentasn algunos aspectos históricos respecto al descubrimiento del agente atiológico del Herpes Zoster. Así mismo, se resaltan sus características clínicas y secuelas en los diferentes sistemas afectados. Se indican pautas de tratamiento para lograr un manejo correcto y minimizar la aparición de sus complicaciones.
Author Biography
Laureano Augusto Osario Gutiérrez, Instituto de Ciencias de la Salud
Dermatólogo, Instituto de Ciencias de la Salud, Medellín.
References
. Peyramond D. Board of consensus of the SP/LF. Management of infections due to the Varicela Zoster Virus. Eur J Dermatol 1998; 8:397-402.
2. McGrary ML, Severson J, Tryng SK. Varicella Zoster Virus. J Am Acad Dermatol 1999; 1-10.
https://doi.org/10.1016/S0190-9622(99)70398-1
3. Ragazzino MW, Melton LJ, Kurland LT, et al.Risk of cancer after Herpes Zoster - a population based Study.N Engl J Med 1982; 307-393-397.
https://doi.org/10.1056/NEJM198208123070701
4. Sterling JC, Kurts JB. Viral infections. En: Textbook of Dermatology, 6a. ed.1998; 1015-1021.
5. Dolin R. Antiviral Drugs. En: Dermatology in Gene ral Medicine, 5a.ed.1999; 2837-2845.
6. Lee AT T. Clinics in Neurology. Herpes Zoster and Postherpetic Neuralgia. J Hong Kong Med Ass 1988; 40:295-298.
7. Hope-Simpson RE.Postherpetic Neuralgia.Herpes Zoster in general practice. J Roy Col Gen Practit 1975; 25:571-575.
8. Morton P, Thompson AN. Oral Acyclovir in the treatment of Herpes Zoster in General Practice. N Zealand Med J 1989; 102:863.
9. Evans TY, Tyring SK. Advances in antiviral therapy inDermatology. En:DermatologicClinic1999(16- 2):409-420.
https://doi.org/10.1016/S0733-8635(05)70022-X
10. Weller S, Blum MR, Doucette M, et al.Pharma cokinetics of the Acyclovir pro-drug Valaciclovir after escalating single and multiple dose administration to normal volunteers. Clin Pharmacol Therap1993; 54:595-605.
https://doi.org/10.1038/clpt.1993.196
11. Wood MJ, Kukla S, Fiddian AP et al. Treatment of Acute Herpes Zoster: Effect of Early (<48h) versus late (48-72h) Therapy with Acyclovir and Valacyclovir on Prolonged Pain. J lnfect Dis 1998; 178(suppl 1):S81-84.
https://doi.org/10.1086/514271
12. Beutner KR, Friedman DJ, Forspaniak C et al. Therapy for Herpes Zoster in lmmunocompetent Adults. Antimicrobial Agents and Chemotherapy 1995; 1546-1553.
https://doi.org/10.1128/AAC.39.7.1546
13. Grand DM, Mauskopf JA, Bell L, et al.Comparison of Valacyclovir and Acyclovir for Treatment of Her pes Zoster in lmmunocompetent Patiens over 50 years of Age: A Costs Consequence Model. Phar macotherapy 1997; 17:333-341.
14. Perry CM, Foulds D. Valacyclovir. A Review of its Antiviral Activity, Pharmacokinetics Properties and Therapeutics Efficacy in Herpesvirus lnfections. Drugs 1996; 52:754-772.
https://doi.org/10.2165/00003495-199652050-00009
15. Hayden FG. Antiviral Agents. En: Pharmacological Basis of Therapeutics. Goodman and Gillman·s (eds), 9a. ed. 1966; 1191-1223.
16. Harris BD, Adal KA, Tomacki KJ.New and Emerging Therapies in lnfectious Diseases.En: Dermatologic Clinic 2000 (18-1):31-37.
https://doi.org/10.1016/S0733-8635(05)70144-3
2. McGrary ML, Severson J, Tryng SK. Varicella Zoster Virus. J Am Acad Dermatol 1999; 1-10.
https://doi.org/10.1016/S0190-9622(99)70398-1
3. Ragazzino MW, Melton LJ, Kurland LT, et al.Risk of cancer after Herpes Zoster - a population based Study.N Engl J Med 1982; 307-393-397.
https://doi.org/10.1056/NEJM198208123070701
4. Sterling JC, Kurts JB. Viral infections. En: Textbook of Dermatology, 6a. ed.1998; 1015-1021.
5. Dolin R. Antiviral Drugs. En: Dermatology in Gene ral Medicine, 5a.ed.1999; 2837-2845.
6. Lee AT T. Clinics in Neurology. Herpes Zoster and Postherpetic Neuralgia. J Hong Kong Med Ass 1988; 40:295-298.
7. Hope-Simpson RE.Postherpetic Neuralgia.Herpes Zoster in general practice. J Roy Col Gen Practit 1975; 25:571-575.
8. Morton P, Thompson AN. Oral Acyclovir in the treatment of Herpes Zoster in General Practice. N Zealand Med J 1989; 102:863.
9. Evans TY, Tyring SK. Advances in antiviral therapy inDermatology. En:DermatologicClinic1999(16- 2):409-420.
https://doi.org/10.1016/S0733-8635(05)70022-X
10. Weller S, Blum MR, Doucette M, et al.Pharma cokinetics of the Acyclovir pro-drug Valaciclovir after escalating single and multiple dose administration to normal volunteers. Clin Pharmacol Therap1993; 54:595-605.
https://doi.org/10.1038/clpt.1993.196
11. Wood MJ, Kukla S, Fiddian AP et al. Treatment of Acute Herpes Zoster: Effect of Early (<48h) versus late (48-72h) Therapy with Acyclovir and Valacyclovir on Prolonged Pain. J lnfect Dis 1998; 178(suppl 1):S81-84.
https://doi.org/10.1086/514271
12. Beutner KR, Friedman DJ, Forspaniak C et al. Therapy for Herpes Zoster in lmmunocompetent Adults. Antimicrobial Agents and Chemotherapy 1995; 1546-1553.
https://doi.org/10.1128/AAC.39.7.1546
13. Grand DM, Mauskopf JA, Bell L, et al.Comparison of Valacyclovir and Acyclovir for Treatment of Her pes Zoster in lmmunocompetent Patiens over 50 years of Age: A Costs Consequence Model. Phar macotherapy 1997; 17:333-341.
14. Perry CM, Foulds D. Valacyclovir. A Review of its Antiviral Activity, Pharmacokinetics Properties and Therapeutics Efficacy in Herpesvirus lnfections. Drugs 1996; 52:754-772.
https://doi.org/10.2165/00003495-199652050-00009
15. Hayden FG. Antiviral Agents. En: Pharmacological Basis of Therapeutics. Goodman and Gillman·s (eds), 9a. ed. 1966; 1191-1223.
16. Harris BD, Adal KA, Tomacki KJ.New and Emerging Therapies in lnfectious Diseases.En: Dermatologic Clinic 2000 (18-1):31-37.
https://doi.org/10.1016/S0733-8635(05)70144-3
How to Cite
1.
Osario Gutiérrez LA. Herpes Zoster Aspectos clínicos y terapéuticos. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2000 Jun. 1 [cited 2024 Jul. 3];8(2):175-80. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/687
Downloads
Download data is not yet available.
Downloads
Published
2000-06-01
How to Cite
1.
Osario Gutiérrez LA. Herpes Zoster Aspectos clínicos y terapéuticos. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2000 Jun. 1 [cited 2024 Jul. 3];8(2):175-80. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/687
Issue
Section
Sin sección en el original
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
